

Barry L Shulkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9471990/publications.pdf>

Version: 2024-02-01

250
papers

8,630
citations

36271

51
h-index

58549

82
g-index

269
all docs

269
docs citations

269
times ranked

6754
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project. <i>Radiology</i> , 2011, 261, 243-257.	3.6	386
2	Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy- d -glucose PET. <i>Radiology</i> , 1999, 212, 35-41.	3.6	299
3	Malignant pheochromocytoma: current status and initiatives for future progress. <i>Endocrine-Related Cancer</i> , 2004, 11, 423-436.	1.6	299
4	Irinotecan+temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 946-957.	5.1	205
5	Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. <i>British Journal of Cancer</i> , 2010, 102, 1319-1326.	2.9	189
6	^{123}I -MIBG Scintigraphy and ^{18}F -FDG PET in Neuroblastoma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1237-1243.	2.8	179
7	Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group. <i>Journal of Nuclear Medicine</i> , 2013, 54, 541-548.	2.8	169
8	Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.. <i>Radiology</i> , 1996, 199, 743-750.	3.6	158
9	Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1445-1452.	0.8	134
10	Pilot Study of Iodine-131+Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2142-2149.	0.8	132
11	Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention. <i>Cell Reports</i> , 2017, 19, 1640-1653.	2.9	127
12	A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 6441-6449.	3.2	116
13	PET and PET/CT in Pediatric Oncology. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 316-331.	2.5	115
14	Resting coronary flow and coronary flow reserve in human infants after repair or palliation of congenital heart defects as measured by positron emission tomography. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1998, 115, 103-110.	0.4	114
15	Use of [18F]Fluorodeoxyglucose Positron Emission Tomography in Evaluating Locally Recurrent and Metastatic Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2665-2671.	1.8	109
16	Renal Function in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial. <i>Journal of Pediatrics</i> , 2010, 156, 66-70.e1.	0.9	109
17	PET-CT in pediatric Langerhans cell histiocytosis. <i>Pediatric Radiology</i> , 2007, 37, 615-622.	1.1	101
18	Intrapericardial paragangliomas (pheochromocytomas): imaging features.. <i>American Journal of Roentgenology</i> , 1997, 168, 109-113.	1.0	99

#	ARTICLE	IF	CITATIONS
19	Differentiating Adrenal Adenomas From Nonadenomas Using 18F-FDG PET/CT. <i>Academic Radiology</i> , 2007, 14, 468-475.	1.3	98
20	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 2160-2169.	0.8	98
21	Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. <i>Blood</i> , 2011, 117, 2614-2617.	0.6	95
22	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. <i>Clinical Cancer Research</i> , 2021, 27, 2179-2189.	3.2	95
23	Guidelines on nuclear medicine imaging in neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2009-2024.	3.3	94
24	Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1128-1134.	0.8	92
25	Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.. <i>Radiology</i> , 1995, 194, 495-500.	3.6	90
26	Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG.. <i>Radiology</i> , 1993, 186, 711-715.	3.6	89
27	Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2011, 17, 6858-6866.	3.2	88
28	Pediatrics: Diagnosis of Neuroblastoma. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 345-353.	2.5	86
29	Treatment of Malignant Pheochromocytomas With 131-I Metaiodobenzylguanidine and Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 364-370.	0.6	86
30	Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. <i>American Journal of Hematology</i> , 2013, 88, 116-119.	2.0	85
31	The Role of 18 F-FDG-PET/CT in Pediatric Sarcoma. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 229-241.	2.5	82
32	Comparison of ¹⁸ F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1381-1386.	0.8	81
33	Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma?. <i>Surgery</i> , 2003, 134, 918-922.	1.0	79
34	Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2006, 47, 865-874.	0.8	79
35	131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 673-681.	2.0	79
36	A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1800-1808.	3.3	76

#	ARTICLE	IF	CITATIONS
37	Procedure Guideline for Diuretic Renography in Children 3.0. Journal of Nuclear Medicine Technology, 2008, 36, 162-168.	0.4	74
38	Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatric Radiology, 2019, 49, 1545-1564.	1.1	71
39	Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends in Endocrinology and Metabolism, 2001, 12, 469-475.	3.1	68
40	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Frontiers in Immunology, 2018, 9, 1355.	2.2	66
41	New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends in Endocrinology and Metabolism, 2005, 16, 66-72.	3.1	65
42	Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncology, The, 2020, 21, 1110-1122.	5.1	63
43	PET/CT Characterization of Fibrous Defects in Children: 18F-FDG Uptake Can Mimic Metastatic Disease. American Journal of Roentgenology, 2006, 187, 1124-1128.	1.0	62
44	A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clinical Cancer Research, 2019, 25, 6320-6328.	3.2	61
45	The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma. Cancer, 2019, 125, 290-297.	2.0	60
46	Gene Expression Profiling of Benign and Malignant Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 541-556.	1.8	59
47	131I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications. Seminars in Nuclear Medicine, 2016, 46, 184-202.	2.5	58
48	Comparison of 18F Fludeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leukemia and Lymphoma, 2007, 48, 699-707.	0.6	54
49	Validation of the mIBG skeletal SIOPEX scoring method in two independent high-risk neuroblastoma populations: the SIOPEX/HR-NBL1 and COG-A3973 trials. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 292-305.	3.3	54
50	Optimization of Pediatric PET/CT. Seminars in Nuclear Medicine, 2017, 47, 258-274.	2.5	53
51	SNMMI Procedure Standard/EANM Practice Guideline on Pediatric ¹⁸ F-FDG PET/CT for Oncology 1.0. Journal of Nuclear Medicine, 2021, 62, 99-110.	2.8	53
52	Primary Extra-Adrenal Pheochromocytoma Positive I-123 MIBG Imaging with Negative I-131 MIBG Imaging. Clinical Nuclear Medicine, 1986, 11, 851-854.	0.7	52
53	Inhibition of Neutral Amino Acid Transport Across the Human Blood-Brain Barrier by Phenylalanine. Journal of Neurochemistry, 1995, 64, 1252-1257.	2.1	52
54	123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEX semi-quantitative reporting method by an international panel. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 234-241.	3.3	52

#	ARTICLE	IF	CITATIONS
55	Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. <i>Journal of Nuclear Medicine</i> , 2018, 59, 502-508.	2.8	52
56	A Pheo-Lurks: Novel Approaches for Locating Occult Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3641-3646.	1.8	51
57	FDG PET imaging of childhood sarcomas. <i>Pediatric Blood and Cancer</i> , 2010, 54, 222-227.	0.8	51
58	¹³¹ I-Metaiodobenzylguanidine Treatment in Patients with Refractory Advanced Neuroblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1992, 15, 226-232.	0.6	50
59	Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 374-382.	1.8	50
60	Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2005, 12, 263-272.	1.6	47
61	FDG positron emission tomography/computed tomography studies of Wilms' tumor. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1300-1308.	3.3	47
62	Distribution of pulmonary blood flow and total lung water during partial liquid ventilation in acute lung injury. <i>Surgery</i> , 1997, 122, 313-323.	1.0	46
63	⁶⁸ Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to ¹²³ I-MIBG SPECT/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 33-41.	3.3	46
64	Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. <i>Journal of Clinical Oncology</i> , 2022, 40, 335-344.	0.8	46
65	Postprocedural symptoms in children who undergo imaging studies of the urinary tract: is it the contrast material or the catheter?. <i>Radiology</i> , 1992, 182, 727-730.	3.6	45
66	SNM Practice Guideline for Brain Death Scintigraphy 2.0. <i>Journal of Nuclear Medicine Technology</i> , 2012, 40, 198-203.	0.4	45
67	PET FDG Studies of Wilms Tumors. <i>The American Journal of Pediatric Hematology/oncology</i> , 1997, 19, 334-338.	1.3	45
68	Evaluation of ¹⁸ F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain Stem Glioma: A Report from the Pediatric Brain Tumor Consortium. <i>Journal of Nuclear Medicine</i> , 2011, 52, 188-195.	2.8	44
69	Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of ¹³¹ I. <i>Journal of Nuclear Medicine</i> , 2003, 44, 898-903.	2.8	43
70	A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. <i>International Journal of Cancer</i> , 2017, 141, 1469-1477.	2.3	42
71	High-Specific-Activity- ¹³¹ I-MIBG versus ¹⁷⁷ Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	3.2	42
72	Comparison of ¹²³ I-metaiodobenzylguanidine (MIBG) and ¹³¹ I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011, 56, 1041-1045.	0.8	40

#	ARTICLE	IF	CITATIONS
73	PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1097-1106.	3.3	40
74	A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3641-3646.	1.8	40
75	PET imaging in pediatric oncology. <i>Pediatric Radiology</i> , 2004, 34, 199-204.	1.1	39
76	¹⁸ F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 25-30.	2.8	39
77	The role of ¹⁸ F-FDG PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 845-853.	1.2	37
78	Use of [¹¹ C]Aminocyclohexanecarboxylate for the Measurement of Amino Acid Uptake and Distribution Volume in Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1990, 10, 727-739.	2.4	36
79	Kasabach-Merritt syndrome: Treatment with epsilon-aminocaproic acid and assessment by indium 111 platelet scintigraphy. <i>Journal of Pediatrics</i> , 1990, 117, 746-749.	0.9	34
80	Pathologic Risk-based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e335-e340.	0.3	34
81	Procedure guideline for brain death scintigraphy. <i>Journal of Nuclear Medicine</i> , 2003, 44, 846-51.	2.8	34
82	Evaluation of the Biodistribution of ¹¹ C-Methionine in Children and Young Adults. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1902-1908.	2.8	32
83	Cerebral glucose metabolism on positron emission tomography of children. <i>Human Brain Mapping</i> , 2014, 35, 2297-2309.	1.9	32
84	FDG PET for the study of primary hepatic malignancies in children. <i>Pediatric Blood and Cancer</i> , 2006, 47, 51-55.	0.8	31
85	Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2276-2283.	0.8	31
86	Survival of Patients with Neuroblastoma Treated with ¹²⁵ I MIBG. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 144-148.	0.6	31
87	Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas. <i>American Journal of Cardiology</i> , 2015, 115, 1753-1759.	0.7	30
88	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26545.	0.8	30
89	Pheochromocytoma, polycythemia and venous thrombosis. <i>American Journal of Medicine</i> , 1987, 83, 773-776.	0.6	29
90	Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. <i>British Journal of Cancer</i> , 2015, 113, 1282-1288.	2.9	29

#	ARTICLE	IF	CITATIONS
91	A Practical, Automated Synthesis of <i>meta</i> -[¹⁸ F]Fluorobenzylguanidine for Clinical Use. ACS Chemical Neuroscience, 2015, 6, 1870-1879.	1.7	29
92	PET in pediatric diseases. Radiologic Clinics of North America, 2005, 43, 135-152.	0.9	28
93	Positron Emission Tomography Detects <i>In Vivo</i> Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma. Cancer Research, 2019, 79, 3112-3124.	0.4	28
94	Role of lymphoscintigraphy and sentinel lymph node biopsy in the management of pediatric melanoma and sarcoma. Pediatric Surgery International, 2012, 28, 571-578.	0.6	27
95	The Role of Imaging Tests in the Diagnosis of Thyroid Carcinoma. Endocrinology and Metabolism Clinics of North America, 1990, 19, 523-543.	1.2	26
96	Cerebral benzodiazepine receptor binding <i>in vivo</i> in patients with recurrent hepatic encephalopathy. Hepatology, 1997, 26, 277-282.	3.6	26
97	⁶⁴ Cu- <i>p</i> -NH ₂ -Bn-DOTA-hu14.18K322A, a PET Radiotracer Targeting Neuroblastoma and Melanoma. Journal of Nuclear Medicine, 2012, 53, 1772-1778.	2.8	26
98	Courses of Malignant Pheochromocytoma: Implications for Therapy. Annals of the New York Academy of Sciences, 2006, 1073, 505-511.	1.8	25
99	Bone and [¹⁸ F]Fluorodeoxyglucose positron-emission tomography/computed tomography scanning for the assessment of osseous involvement in Hodgkin lymphoma in children and young adults. Leukemia and Lymphoma, 2009, 50, 1794-1802.	0.6	25
100	Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. European Journal of Haematology, 2014, 93, 377-383.	1.1	25
101	FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up. Pediatric Radiology, 2015, 45, 1308-1315.	1.1	25
102	Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. Radiology, 2018, 287, 303-312.	3.6	25
103	Radionuclide Imaging of Infection and Inflammation in Children: a Review. Seminars in Nuclear Medicine, 2018, 48, 148-165.	2.5	25
104	Long-term renal function after treatment for unilateral, nonsyndromic Wilms tumor. A report from the St. Jude Lifetime Cohort Study. Pediatric Blood and Cancer, 2020, 67, e28271.	0.8	24
105	Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with Hodgkin lymphoma. Pediatric Blood and Cancer, 2008, 51, 198-203.	0.8	23
106	Retrospective Evaluation of PET-MRI Registration Algorithms. Journal of Digital Imaging, 2011, 24, 485-493.	1.6	21
107	Efficient automated syntheses of high specific activity 6-[¹⁸ F]fluorodopamine using a diaryliodonium salt precursor. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 30-34.	0.5	21
108	Iodine-131 Metaiodobenzylguanidine Uptake in Infantile Myofibromatosis. Clinical Nuclear Medicine, 1989, 14, 344-346.	0.7	20

#	ARTICLE	IF	CITATIONS
109	FDG PET imaging of paragangliomas of the neck: comparison with MIBG SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 1347-1350.	2.2	20
110	Successive distinct high-grade gliomas in L-2-hydroxyglutaric aciduria. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 273-277.	1.7	20
111	Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1207-1213.	0.8	20
112	Radiomics Features Differentiate Between Normal and Tumoral High-Fdg Uptake. <i>Scientific Reports</i> , 2018, 8, 3913.	1.6	20
113	Age-Specific ¹⁸ F-FDG Image Processing Pipelines and Analysis Are Essential for Individual Mapping of Seizure Foci in Pediatric Patients with Intractable Epilepsy. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1590-1596.	2.8	20
114	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. <i>Clinical Cancer Research</i> , 2019, 25, 6044-6051.	3.2	20
115	Technical issues in performing PET studies in pediatric patients. <i>Journal of Nuclear Medicine Technology</i> , 2004, 32, 5-9; quiz 10-1.	0.4	20
116	Differentiation Between Carcinoid and Sarcoid With F-18 FDG PET and In-111 Pentetreotide. <i>Clinical Nuclear Medicine</i> , 2006, 31, 197-200.	0.7	19
117	¹¹ C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 163-170.	1.4	19
118	Comparison of ¹¹ C-Methionine and ¹⁸ F-FDG PET/CT for Staging and Follow-up of Pediatric Lymphoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 419-424.	2.8	19
119	Role of Limited Whole-Body PET/CT in Pediatric Lymphoma. <i>American Journal of Roentgenology</i> , 2011, 196, 1047-1055.	1.0	18
120	Renaissance of ¹⁸ F-FDG Positron Emission Tomography in the Imaging of Pheochromocytoma/Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2337-2339.	1.8	18
121	Ultralow dose computed tomography attenuation correction for pediatric PET CT using adaptive statistical iterative reconstruction. <i>Medical Physics</i> , 2015, 42, 558-566.	1.6	18
122	Evaluation of ¹¹ C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 312-319.	2.8	18
123	Metabolic response as assessed by ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. <i>Cancer Medicine</i> , 2021, 10, 857-866.	1.3	18
124	Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29644.	0.8	18
125	Establishing Age-Associated Normative Ranges of the Cerebral ¹⁸ F-FDG Uptake Ratio in Children. <i>Journal of Nuclear Medicine</i> , 2015, 56, 575-579.	2.8	17
126	Efficacy of radioactive iodine treatment of gravesâ™ hyperthyroidism using a single calculated ¹³¹ I dose. <i>Clinical Diabetes and Endocrinology</i> , 2018, 4, 20.	1.3	17

#	ARTICLE	IF	CITATIONS
127	A safety and feasibility trial of ¹³¹ I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29117.	0.8	17
128	α -Adrenergic Antagonist Inhibition of Hepatic 3,5,3'-Triiodothyronine Production*. <i>Endocrinology</i> , 1984, 115, 858-861.	1.4	16
129	Effect of Aspartame-Derived Phenylalanine on Neutral Amino Acid Uptake in Human Brain: A Positron Emission Tomography Study. <i>Journal of Neurochemistry</i> , 1991, 56, 1526-1535.	2.1	16
130	MIBG detection of hepatic neuroblastoma: Correlation with CT, US and surgical findings. <i>Pediatric Radiology</i> , 1993, 23, 276-280.	1.1	16
131	Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma. <i>Haematologica</i> , 2010, 95, 1691-1696.	1.7	16
132	Regional Brain Glucose Metabolism and Neurocognitive Function in Adult Survivors of Childhood Cancer Treated with Cranial Radiation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1805-1810.	2.8	16
133	FDG PET/CT appearance of local osteosarcoma recurrences in pediatric patients. <i>Pediatric Radiology</i> , 2017, 47, 1800-1808.	1.1	16
134	Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3927-3937.	0.8	16
135	Reverse Triiodothyronine Does Not Alter Pituitary Thyroid Function in Normal Subjects*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1984, 58, 1184-1187.	1.8	15
136	Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) in pediatric and young adult patients: Results from a prospective study using limited-margin radiotherapy. <i>Cancer</i> , 2017, 123, 4419-4429.	2.0	15
137	Simultaneous pancreatic-renal transplant scintigraphy. <i>American Journal of Roentgenology</i> , 1986, 147, 1193-1196.	1.0	14
138	Efficacy of anterior gastric fundoplication in the treatment of gastroesophageal reflux in infants and children. <i>Journal of Pediatric Surgery</i> , 1994, 29, 1071-1075.	0.8	14
139	Pediatric Positron Emission Tomography-Computed Tomography Protocol Considerations. <i>Seminars in Ultrasound, CT and MRI</i> , 2008, 29, 271-276.	0.7	14
140	Biochemical testing for neuroblastoma using plasma free 3-methyldopa, 3-methoxytyramine, and normetanephrine. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28081.	0.8	14
141	PET with 18F-Fluorodeoxyglucose/Computed Tomography in the Management of Pediatric Sarcoma. <i>PET Clinics</i> , 2020, 15, 333-347.	1.5	14
142	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 490.e1-490.e8.	0.6	14
143	Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3852-3869.	3.3	14
144	The Role of PET/CT in Assessing Pulmonary Nodules in Children With Solid Malignancies. <i>American Journal of Roentgenology</i> , 2013, 201, W900-W905.	1.0	13

#	ARTICLE	IF	CITATIONS
145	Thyroid Cancer in Children. <i>Journal of Nuclear Medicine</i> , 2014, 55, 705-707.	2.8	13
146	Compared to 123I-MIBG SPECT/CT, 18F-DOPA PET/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma. <i>Annals of Nuclear Medicine</i> , 2017, 31, 357-365.	1.2	13
147	Infiltrative cerebellar ganglioglioma: conventional and advanced MRI, proton MR spectroscopic, and FDG PET findings in an 18-month-old child. <i>Clinical Radiology</i> , 2011, 66, 194-201.	0.5	12
148	Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma. <i>EJNMMI Physics</i> , 2019, 6, 31.	1.3	12
149	Scintigraphic Portrayal of the Syndrome of Multiple Endocrine Neoplasia Type-2B. <i>Clinical Nuclear Medicine</i> , 1988, 13, 433-437.	0.7	11
150	Multimodality Imaging of Malignant Pheochromocytoma. <i>Clinical Nuclear Medicine</i> , 2006, 31, 822-825.	0.7	11
151	PET/CT in the Evaluation of Neuroblastoma. <i>PET Clinics</i> , 2008, 3, 551-561.	1.5	11
152	Histiocyte-rich Xanthomatous Pseudotumor Mimicking Relapse on Positron Emission Tomography Imaging in an Adolescent With Primary Mediastinal Diffuse Large B-cell Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 232-235.	0.3	11
153	Evaluation of children with craniopharyngioma using carbon-11 methionine PET prior to proton therapy. <i>Neuro-Oncology</i> , 2013, 15, 506-510.	0.6	11
154	Postoperative cerebral glucose metabolism in pediatric patients receiving proton therapy for craniopharyngioma. <i>Journal of Neurosurgery: Pediatrics</i> , 2015, 16, 567-573.	0.8	11
155	Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-CD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10534-10534.	0.8	11
156	Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences. <i>Cancer</i> , 2022, 128, 606-614.	2.0	11
157	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 4107-4118.	0.8	11
158	Role of MR Imaging and Iodine 123 MIBG Scintigraphy in Staging of Pediatric Neuroblastoma [letter]. <i>Radiology</i> , 2003, 227, 908-909.	3.6	10
159	PET-CT of the Normal Spinal Cord in Children. <i>Academic Radiology</i> , 2009, 16, 881-885.	1.3	10
160	Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion. <i>Blood Advances</i> , 2020, 4, 2991-2995.	2.5	10
161	Amiodarone-Induced Hyperthyroidism in a Patient with Functioning Papillary Carcinoma of the Thyroid and Extensive Hepatic Metastases. <i>Thyroid</i> , 2005, 15, 1337-1340.	2.4	9
162	ABNM Position Statement: Nuclear Medicine Professional Competency and Scope of Practice. <i>Journal of Nuclear Medicine</i> , 2011, 52, 994-997.	2.8	9

#	ARTICLE	IF	CITATIONS
163	18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10549-10549.	0.8	9
164	Multiple Chemodectomas. Clinical Nuclear Medicine, 1994, 19, 527-531.	0.7	8
165	Dose optimization: a review of CT imaging for PET attenuation correction. Clinical and Translational Imaging, 2017, 5, 359-371.	1.1	8
166	Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatric Blood and Cancer, 2019, 66, e27736.	0.8	8
167	Effect of Propranolol on 18F-Fluorodeoxyglucose Uptake in Brown Adipose Tissue in Children and Young Adults with Neoplastic Diseases. Molecular Imaging and Biology, 2021, 23, 260-269.	1.3	8
168	Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series. Journal of Pediatric Hematology/Oncology, 2021, 43, e692-e696.	0.3	8
169	Whole-Body Pediatric Neuroblastoma Imaging. Clinical Nuclear Medicine, 2015, 40, 737-739.	0.7	7
170	FDG-PET CT in the evaluation of primary and secondary pancreatic malignancies. Pediatric Blood and Cancer, 2018, 65, e27115.	0.8	7
171	The role of routine imaging in pediatric cutaneous melanoma. Pediatric Blood and Cancer, 2018, 65, e27412.	0.8	7
172	Value of the Sentinel Node Procedure in Pediatric Extremity Rhabdomyosarcoma: A Systematic Review and Retrospective Cohort Study. Annals of Surgical Oncology, 2021, 28, 9048-9059.	0.7	7
173	Platelet reactivity in human aortic grafts: A prospective, randomized midterm study of platelet adherence and release products in Dacron and polytetrafluoroethylene conduits. Journal of Vascular Surgery, 1989, 9, 0234-0243.	0.6	7
174	A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children's Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 10017-10017.	0.8	7
175	Thyroid hormone analog inhibition of hepatic 5-iodothyroine deiodinase activity. Journal of Endocrinological Investigation, 1988, 11, 657-661.	1.8	6
176	Mediastinal Seminoma in a Patient With Wiskott-Aldrich Syndrome. Journal of Pediatric Hematology/Oncology, 2002, 24, 672-676.	0.3	6
177	Conjoint Statement of the SNM, ACNM, and ABNM on Credentialing and Delineation of Privileges for Therapeutic Procedures Using Radiopharmaceuticals: TABLE 1.. Journal of Nuclear Medicine, 2011, 52, 323-326.	2.8	6
178	Impact of Post-Induction Curie Scores in High-Risk Neuroblastoma. Biology of Blood and Marrow Transplantation, 2015, 21, S107.	2.0	6
179	Pediatric Musculoskeletal Imaging. PET Clinics, 2019, 14, 145-174.	1.5	6
180	18F-2-fluoro-2-deoxyglucose uptake in white adipose tissue on pediatric oncologic positron emission tomography (PET)/computed tomography (CT). Pediatric Radiology, 2020, 50, 524-533.	1.1	6

#	ARTICLE	IF	CITATIONS
181	Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 172-180.	0.4	6
182	Early results from Children's Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10015-10015.	0.8	6
183	A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10003-10003.	0.8	6
184	Bilateral Testicular Neuroblastoma Scintigraphic Depiction and Therapy with I-131 MIBG. <i>Clinical Nuclear Medicine</i> , 1992, 17, 638-642.	0.7	5
185	Radiation-Induced Osteosarcoma and Papillary Carcinoma of the Thyroid. <i>Clinical Nuclear Medicine</i> , 2006, 31, 5-8.	0.7	5
186	FDG-PET/CT Prior or Subsequent to Radiation is a Poor Predictor of Local Outcome in Patients with Group III Rhabdomyosarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S116.	0.4	5
187	Managing local/regional failure in children with high-risk neuroblastoma: A single institution experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27408.	0.8	5
188	SPECT Imaging of Myocarditis. <i>Clinical Nuclear Medicine</i> , 1987, 12, 841-842.	0.7	4
189	Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27417.	0.8	4
190	Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28096.	0.8	4
191	[11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.120.261891.	2.8	4
192	MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study.. <i>Journal of Clinical Oncology</i> , 2010, 28, 9516-9516.	0.8	4
193	Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10502-10502.	0.8	4
194	Preincubation of Thyroxine with Sulfhydryl-Reducing Agents Does Not Stimulate Thyroxine Inner or Outer Ring Deiodination*. <i>Endocrinology</i> , 1983, 113, 851-854.	1.4	3
195	18F-Fluorodeoxyglucose PET/CT in Childhood Lymphoma. <i>PET Clinics</i> , 2006, 1, 265-273.	1.5	3
196	Developmental Venous Anomalies Mimicking Neoplasm on 11C-Methionine PET and DSC Perfusion MRI. <i>Clinical Nuclear Medicine</i> , 2017, 42, e275-e276.	0.7	3
197	Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10508-10508.	0.8	3
198	Caloric Restriction Does not Alter Thyrotropin Secretion in Hypothyroidism*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1985, 60, 1076-1080.	1.8	2

#	ARTICLE	IF	CITATIONS
199	Uptake of Tc-99m MDP in Soft Tissue Calcific Deposits Due to the Tumor Lysis Syndrome. <i>Clinical Nuclear Medicine</i> , 1988, 13, 765-767.	0.7	2
200	Flare Response in Ewing's Sarcoma. <i>Clinical Nuclear Medicine</i> , 1991, 16, 807-809.	0.7	2
201	Splenic Infarction Detection by In-111 Leukocyte Scintigraphy. <i>Clinical Nuclear Medicine</i> , 1992, 17, 822.	0.7	2
202	Thoracic neural crest tumors in Beckwith-Wiedemann syndrome. <i>Medical and Pediatric Oncology</i> , 2003, 41, 468-469.	1.0	2
203	Reply: ¹²³ I-MIBG Scintigraphy and ¹⁸ F-FDG PET in Neuroblastoma. <i>Journal of Nuclear Medicine</i> , 2010, 51, 331-331.	2.8	2
204	Assessment of Chemotherapy Response in Ewing Sarcoma. <i>Radiology</i> , 2016, 281, 647-649.	3.6	2
205	Reply: The Need for Prudence When Using ¹⁸ F-FDG PET as a Reference Standard for Lymphoma Detection. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1355.1-1355.	2.8	2
206	Management of Local-Regional Failure in Children With High-Risk Neuroblastoma: A Single Institution Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E570-E571.	0.4	2
207	CT-based SPECT attenuation correction and assessment of infarct size: results from a cardiac phantom study. <i>Annals of Nuclear Medicine</i> , 2017, 31, 764-772.	1.2	2
208	Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 134, 89-95.	0.3	2
209	Pictorial review of the clinical applications of MIBG in neuroblastoma: current practices. <i>Clinical and Translational Imaging</i> , 2020, 8, 483-507.	1.1	2
210	Paget Disease of the Thumb. <i>Clinical Nuclear Medicine</i> , 1999, 24, 613-614.	0.7	2
211	Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 42-50.	0.9	2
212	Scintigraphic detection of sinusitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1988, 14, 552-4.	2.2	1
213	Hot Nodule After Fine Needle Aspiration. <i>Clinical Nuclear Medicine</i> , 1988, 13, 131.	0.7	1
214	Dual Photon Absorptiometry The Importance of Clinical Correlation. <i>Clinical Nuclear Medicine</i> , 1988, 13, 175-176.	0.7	1
215	Advances in Imaging of Nonthyroid Endocrine Neoplasms. <i>Problems in General Surgery</i> , 2003, 20, 11-20.	0.2	1
216	Long-term Toxicities of a Prospective Trial Delivering Limited Margin 3DCRT/IMRT in Children With Rhabdomyosarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S69-S70.	0.4	1

#	ARTICLE	IF	CITATIONS
217	A Novel Methodology for Anatomically and Biologically Determined Clinical Target Volume Margin Estimation in Pediatric High Grade Glioma. International Journal of Radiation Oncology Biology Physics, 2017, 99, S175-S176.	0.4	1
218	Questions and comments about ⁶⁷ Pediatric applications of Dotatate: early diagnostic and therapeutic experience SM . Pediatric Radiology, 2021, 51, 495-496.	1.1	1
219	Pediatric Oncology. , 2007, , 404-418.		1
220	Neuroblastoma: Functional Imaging. , 2014, , 429-445.		1
221	Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma trials.. Journal of Clinical Oncology, 2014, 32, 10029-10029.	0.8	1
222	Validation of postinduction Curie scores in high-risk neuroblastoma.. Journal of Clinical Oncology, 2014, 32, 10031-10031.	0.8	1
223	PET Imaging in Pediatric Disorders. , 2006, , 337-357.		1
224	Multi-level otsu method to define metabolic tumor volume in positron emission tomography. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 373-386.	1.0	1
225	Unusual Uptake of In-111 Labeled Platelets in a Patient with Polycythemia. Clinical Nuclear Medicine, 1988, 13, 917-918.	0.7	0
226	Quantification of Bone Mineralization by Dual Photon Absorptiometry in Osteopetrosis. Clinical Nuclear Medicine, 1989, 14, 544-545.	0.7	0
227	Intraluminal Hematoma. Clinical Nuclear Medicine, 1995, 20, 1095.	0.7	0
228	Early Results of a Prospective Study Delivering Limited Margin Radiotherapy for Pediatric Patients with Ewing's Sarcoma Family of Tumors. International Journal of Radiation Oncology Biology Physics, 2009, 75, S41.	0.4	0
229	Feasibility of Biological Image Guided Radiotherapy for Pediatric Rhabdomyosarcoma Based on FDG PET. International Journal of Radiation Oncology Biology Physics, 2009, 75, S512.	0.4	0
230	Evaluation of the Use of Carbon-11 Methionine PET Scans in Pediatric Patients With Craniopharyngioma. International Journal of Radiation Oncology Biology Physics, 2012, 84, S163.	0.4	0
231	Pediatric. Medical Radiology, 2012, , 253-277.	0.0	0
232	Postoperative Metabolic Abnormality in Craniopharyngioma Patients Before Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, S592.	0.4	0
233	Long-term Cerebral Glucose Distribution in Craniopharyngioma, Ependymoma, and Low-Grade Astrocytoma Patients After Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, E505-E506.	0.4	0
234	Role of MIBG Studies in Prognostication and Prediction of Metastatic Site Failure in Pediatric Patients with High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, S27-S28.	0.4	0

#	ARTICLE	IF	CITATIONS
235	Cerebral Glucose Metabolism in Children with Craniopharyngioma Treated With Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E568.	0.4	0
236	Radioisotope Therapies: Iodine-131, I-131-MIBG, and Beyond. Pediatric Oncology, 2019, , 275-303.	0.5	0
237	ASO Visual Abstract: The Value of the Sentinel Node Procedure in Pediatric Extremity Rhabdomyosarcoma—A Systematic Review and Retrospective Cohort Study. Annals of Surgical Oncology, 2021, 28, 472-473.	0.7	0
238	TH-E-M100J-07: Changes in Standardized Uptake Value of Brain Tissues in Pediatric Brain Tumor Patients Treated with Chemoradiotherapy. Medical Physics, 2007, 34, 2650-2650.	1.6	0
239	MO-D-141-04: Brown Adipose Tissue Uptake Comparison Between Pharmacological and Environmental Control in a Pediatric PET Facility. Medical Physics, 2013, 40, 399-400.	1.6	0
240	TSH and Thyroidal Responses to Continuous and Intermittent TRH Administration. , 1986, , 285-290.		0
241	Splenosis in a Patient With Autoimmune Thrombocytopenia. Clinical Nuclear Medicine, 1996, 21, 61-62.	0.7	0
242	Comparison of ¹⁸ F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma.. Journal of Clinical Oncology, 2015, 33, 10047-10047.	0.8	0
243	SUâ€œâ€œâ€œ86: Ultraâ€œLow Dose Computed Tomography Attenuation Correction for Pediatric PET CT Using Adaptive Statistical Iterative Reconstruction (ASiRâ„‚,c). Medical Physics, 2015, 42, 3262-3262.	1.6	0
244	Other Neoplasms. , 2016, , 337-347.		0
245	Computer-assisted Curie scoring for metaiodobenzylguanidine (mIBG) scans in patients with neuroblastoma.. Journal of Clinical Oncology, 2016, 34, 10559-10559.	0.8	0
246	Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10526-10526.	0.8	0
247	Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma.. Journal of Clinical Oncology, 2017, 35, 10557-10557.	0.8	0
248	Long-term renal function after treatment for Wilms tumor: A report from the St. Jude Lifetime Cohort (SJLIFE) study.. Journal of Clinical Oncology, 2018, 36, 10566-10566.	0.8	0
249	Pediatric Nuclear Medicine: Technical Aspects. , 2021, , .		0
250	Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2022, 40, 10027-10027.	0.8	0